Andrew Smith | Authors

August 26, 2022

According to experts, routine biomarker testing has become a standard part of care for several common tumor types.

June 15, 2022

Most studies of how timing affects immunotherapy efficacy have defined “timing” relative to other treatments, but some research has investigated the impact of giving patients immunotherapy at different times of day.

October 02, 2021

Up to 60% of patients undergoing active treatment and a third of cancer survivors report significant pain stemming either from their cancer itself or their cancer treatments. The most common treatment for significant cancer- related pain is opioid medication.

December 05, 2020

After decades of use in clinical settings, targeted therapies now enjoy favored status in the cancer treatment landscape.

March 11, 2019

Ongoing research seeks to boost objective response rates in urothelial cancer by developing biomarkers to predict which immune checkpoint inhibitors a patient is most likely to respond to and by testing these in combination with each other and other treatment types to increase both the number and duration of responses.

December 26, 2018

New draft guidelines from the FDA endorse the use of multiple expansion cohorts in first-in-human clinical trials as a means of speeding lifesaving medications to market, but the document warns that the difficulties and dangers of using such complex studies so early in the testing process necessitate unusually careful design and oversight.